title: [BCG and radiotherapy: the compatibility of 2 conservative treatments for cancer of the urinary bladder].
abstract: OBJECTIVE
  To review the efficacy of radiotherapy and BCG in the treatment of transitional cell carcinoma of the urinary bladder in its different forms of presentation, with special reference to patients with infiltrating bladder tumors receiving radiotherapy and those in whom the lesion recurs as a high grade superficial bladder tumor.
  
  
  RESULTS
  10 patients who previously received radiotherapy for T2-4 infiltrating bladder tumor that recurred as a high grade superficial tumor were treated with BCG. Four patients are alive and disease-free with a preserved bladder at 2-8 years follow-up. Four other patients who required cystectomy for persistence or progression of the tumor to the bladder wall, are alive and disease free at 3-7 years follow-up. The remaining two patients who were not amenable to major surgery died from the disease more than two years after treatment with BCG. BCG was well-tolerated by 70% of the patients and the rest showed minor complications.
  
  
  CONCLUSIONS
  28.3% of recurrences after radiotherapy are superficial tumors and 7% are carcinoma in situ. The appearance of carcinoma in situ or T1 G3 lesions following radiotherapy of the bladder questions its efficacy against these superficial forms for which cystectomy is reserved. BCG has been found to be effective in high grade superficial bladder tumors that have not been previously irradiated, therefore it would be acceptable to extend its application to those patients in whom radiotherapy has achieved control of the infiltrating tumor but not the high grade superficial tumor. The 40-70% of patients who are alive with a preserved bladder appears to be sufficient to recommend BCG salvage for high grade superficial bladder tumors post-radiotherapy. BCG therapy does not entail major complications or compromise patient survival, including those cases that will require cystectomy.
authors.affiliation: Servicio de Urología, Hospital Verge de la Cinta, Tortosa, Tarragona, España. pasama@maestrat.net
authors.forename: F M
authors.initials: FM
authors.lastname: Sánchez-Martín
authors.forename: J
authors.initials: J
authors.lastname: Palou Redorta
authors.forename: R
authors.initials: R
authors.lastname: Regalado Pareja
authors.forename: J
authors.initials: J
authors.lastname: Rubio Briones
authors.forename: H
authors.initials: H
authors.lastname: Villavicencio Mavric
authors.forename: J
authors.initials: J
authors.lastname: Vicente Rodríguez
mesh_terms: D001500:BCG Vaccine / Q000009:adverse effects / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D015653:Cystectomy; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy; D001743:Urinary Bladder / Q000187:drug effects / Q000528:radiation effects; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*
chemical_list: D001500:BCG Vaccine